Search by Department
Dr. Peter Q. Eichacker's primary research interests have been the pathogenesis and treatment of septic shock, sepsis induced lung injury related to commonly encountered types of bacteria as well as to the less-common anthrax bacterium, and anthrax-related cardiovascular injury.
Dr. Eichacker is a Senior Investigator and Head of the Critical Care Medicine Section in the NIH Clinical Center's Critical Care Medicine Department.
He earned his undergraduate degree from Boston University and his medical degree from New York University. After he completed a residency and chief residency in internal medicine, he had a fellowship in Pulmonary Medicine at Bronx Municipal Hospital Center and Hospital of the Albert Einstein College of Medicine in New York.
Dr. Eichacker joined the National Institutes of Health in 1986 as a CCMD fellow. In 1990, he was appointed Senior Investigator and Head of the Critical Care Medicine section in CCMD.
Dr. Eichacker's research has provided critical insights into key factors influencing the effectiveness of immunomodulatory agents in the treatment of sepsis. This work has been taken into account by the US Food and Drug Administration as it evaluates the potential application of new therapies for sepsis.
His research in the area of septic shock related to anthrax infection and the models he has developed to do that research with are unique and have provided insights not possible in other laboratories. This work has been instrumental in providing a basis for the inclusion of an anthrax toxin directed antibody therapy in the National Strategic Stockpile.
Dr. Eichacker serves as a consultant to both NIAID and the FDA on issues pertaining both to the treatment of sepsis in general and anthrax in particular.
Books and Book Chapter
Eichacker PQ, Pugin J, editors. Evolving Concepts in Sepsis and Septic Shock. Norwell: Kluwer Academic Publishers; 2000.
Remy KE, Cui X, Solomon SB, Sun J, Migone T, Bolmer SD, Al-Hamad M, Li Y, Fitz Y, Eichacker PQ. Hemodynamic support and early treatment with protective antigen directed monoclonal antibody together improve survival in a canine model of anthrax edema toxin induced shock. Intensive Care Med in press. 2015.
Booth M,Donaldson L, Cui X, Sun J, Cole S, Dailsey S, Hart A, Johns N, McConnell P,McLennan T, Parcell B, Robb H, Shippey B, Sim M, Wallis C, Eichacker PQ. Confirmed B. anthracis infection among persons who inject drugs, Scotland, 2009-2010. Emerging Infectious Diseases. 2014; 20: 1452-1463.
Jaswal DS, Leung JM, Sun J, Cui X, Li Y, Kern S, Welsh J, Natanson C, Eichacker PQ. Tidal volume and plateau pressure use for acute lung injury from 2000 to Present: a systematic literature review. Crit Care Med.2014; 42: 2278-2289.
Remy KE, Qiu P, Li Y, Cui X, Eichacker PQ. B. anthracis associated cardiovascular dysfunction and shock: the potential contribution of both non-toxin and toxin components. BMC Medicine. 2013. 2013 Oct 9;11:217.
Barochia AV, Cui X, Eichacker PQ. The surviving sepsis campaign's revised sepsis bundles. Curr Infect Dis Rep. 2013 Oct; 15 (5): 385-393.
Li Y, Cui X, Solomon S, Fitz Y, Eichacker PQ. B. anthracis edema toxin increases cAMP levels and inhibits phenylephrine stimulated contraction in a rat aortic ring model. Manuscript submitted. Am J Physiol. 2013; 305: H238 - H250.
Qiu P, Cui X, Li Y, Fitz Y, Eichacker PQ. Bacillus anthracis cell wall peptidoglycan but not lethal or edema toxins, produces changes consistent with disseminated intravascular cagulation in a rat model. J Infect Dis. 2013; 208: 978 - 989.
Hicks CW, Sweeney DA, Cui X, Li Y, Eichacker PQ. An overview of anthrax infection including the recently identified form of disease in injection drug users. Intensive Care Med. 2012 Jul;38(7):1092-104.
Barochia AV, Cui X, Sun J, Li Y, Solomon SB, Migone TS, Subramanian GM, Bolmer SD, Eichacker PQ. Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines. J Infect Dis. 2012 Mar 1;205(5):818-29.
Hicks CW, Cui X, Sweeney DA, Li Y, Barochia A, Eichacker PQ. The potential contributions of lethal and edema toxins to the pathogenesis of anthrax associated shock. Toxins (Basel). 2011 Sep;3(9):1185-202.
Qiu P, Cui X, Barochia A, Li Y, Natanson C, Eichacker PQ. The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death. Expert Opin Investig Drugs. 2011 Nov;20(11):1555-64.
Sweeney DA, Hicks CW, Cui X, Li Y, Eichacker PQ. Anthrax infection. Am J Respir Crit Care Med. 2011 Dec 15;184(12):1333-41.
Sweeney DA, Cui X, Solomon SB, Vitberg DA, Migone TS, Scher D, Danner RL, Natanson C, Subramanian GM, Eichacker PQ. Anthrax lethal and edema toxins produce different patterns of cardiovascular and renal dysfunction and synergistically decrease survival in canines. J Infect Dis. 2010 Dec 15;202(12):1885-96.
Cui X, Su J, Li Y, Shiloach J, Solomon S, Kaufman JB, Mani H, Fitz Y, Weng J, Altaweel L, Besch V, Eichacker PQ. Bacillus anthracis cell wall produces injurious inflammation but paradoxically decreases the lethality of anthrax lethal toxin in a rat model. Intensive Care Med. 2010 Jan;36(1):148-56.
Li Y, Cui X, Su J, Haley M, Macarthur H, Sherer K, Moayeri M, Leppla SH, Fitz Y, Eichacker PQ. Norepinephrine increases blood pressure but not survival with anthrax lethal toxin in rats. Crit Care Med. 2009 Apr;37(4):1348-54.
Su J, Li X, Cui X, Li Y, Fitz Y, Hsu L, Mani H, Quezado M, Eichacker PQ. Ethyl pyruvate decreased early nuclear factor-kappaB levels but worsened survival in lipopolysaccharide-challenged mice. Crit Care Med. 2008 Apr;36(4):1059-67.
Sherer K, Li Y, Cui X, Eichacker PQ. Perspective on the roles of lethal and edema toxins in the pathogenesis of B. anthracis septic shock: Implications for therapy. Am J Respir Crit Care Med. 2007; 175: 211-221.
Cui X, Li Y, Li X, Laird MW, Subramanian M, Moayeri M, Leppla SH, Fitz Y, Su J, Sherer K, Eichacker PQ. B. anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model. J Infect Dis 2007; 195: 572-580.
Eichacker PQ, Natanson C, Danner RL. Surviving sepsis - practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med. 2006; 355: 1640-1642.
Li X, Cui X, Li Y, Fitz Y, Hsu L, Eichacker PQ. Parthenolide has limited effects on nuclear factor-kappa beta increases and worsens survival in lipopolysaccharide challenged C57BL/6J mice. Cytokine. 2006; 33: 299-308.
Cui X, Li Y, Li X, Haley M, Moayeri M, Fitz Y, Banks SM, Leppla SH, Eichacker PQ. Sublethal doses of B. anthracis lethal toxin inhibit inflammation with LPS and E. coli challenge but have opposite effects on survival. J Infect Dis. 2006; 193: 829-840.
Solomon S, Cui X, Gerstenberger E, Natanson C, Danner RL, Fitz Y, Banks SM, Suganuma A, Eichacker PQ. Effective dosing in rats of lipid A analogue E5564 in rats depends on timing of treatment and route of infection. J Infect Dis. 2006; 193: 634-644.
Haley M, Parent C, Cui X, Fitz Y, Correa-Araujo R, Danner RL, Banks SM, Natanson C, Eichacker PQ. Neutrophil inhibition with L-selectin MAb improves or worsens survival dependent on route but not severity of infectious challenge in a rat E. coli sepsis model. J Appl Physiol.2005; 98: 2155-2162.
Cui X, Li Y, Moayeri M, Choi GH, Subramanian GM, Li X, Haley M, Fitz Y, Feng J, Banks SM, Leppla SH, Eichacker PQ. Late treatment with protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin infused rat model of anthrax sepsis. J Infect Dis. 2005; 191: 422-434.
Cui X, Parent C, Gerstenberger E, Solomon S, Fitz Y, Danner R, Banks SM, Natanson C, Eichacker PQ. Severity of sepsis alters the effects of superoxide anion inhibition in a rat model of sepsis. J Appl Physio 2004; 97: 1349-1357.
Cui X, Moayeri M, Li Y, Fitz Y, Correa-Araujo R, Gladwin M, Banks SM, Natanson C, Leppla SH, Eichacker PQ. Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats. Am J Physiol 2004; 286: R699-R709.
- NIH Clinical Directors Award for Participation in the Electronic Flow Sheet project, 2011
- NIH Clinical Directors Award for Research on Anthrax, 2007
- Clinical Center Patient Safety Champion Award, 2007
- Trans-NIH/FDA Biodefense Program grant (3 years), 2008
- Trans-NIH/FDA Biodefense Program grant (3 years), 2005
- PHS Outstanding Unit Citation Award, 2004
- PHS Outstanding Unit Citation Award, 2003
- NIH Clinical Center Director's Award, 1999
- Washington D.C. Area Critical Care Society Research Award, 1999
- Society of Critical Care Medicine President's Citation Award, 1998
- PHS Commendation Medal, 1994
- Society of Critical Care Medicine(SCCM) Award for Finest Young Investigator, 1994
- Fellowship, American College of Chest Physicians, 1994
- Society of Critical Care Medicine (SCCM) Award for Finest Poster Presentation, 1993
NOTE: PDF documents require the free Adobe Reader.
This page last updated on 03/14/2019